The Cancer Service Line (CSL) and the Penn Center for Cancer Care Innovation (PC3I) at the Abramson Cancer Center (ACC) are delighted to announce the selection of the 2022 Access Accelerator project.
Over the next six months, this team will work closely with innovation and operational support from CSL and PC3I to design and test an intervention to improve patient access to hematologic oncology care. They will also receive mentorship and advising from a broad group of stakeholders representing both inpatient and outpatient hematologic care as well as health system operations and leadership. At the conclusion of the pilot, the project team will present its progress and findings and identify opportunities for scale.
The Penn Center for Cancer Care Innovation is proud to announce that PC3I Fellow John Lin, MD, has won a Young Investigator Award from Conquer Cancer, the ASCO Foundation.
This randomized trial leverages peer comparisons to combat physician optimism bias found improved hospice utilization metrics among a group of academic oncologists.
PC3I examined patients' attitudes and beliefs related to colorectal cancer screening, assessing motivators, barriers, and facilitators to screening and how financial incentives may or may not affect their decision to be screened.